Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

This study is combining two experimental cancer drugs — a RAS inhibitor (which targets a common cancer-driving gene mutation) and ivonescimab (an immunotherapy drug) — to treat advanced solid tumors with RAS mutations such as KRAS, HRAS, or NRAS. The trial is testing different dose combinations to find the safest and most effective approach. **You may be eligible if...** - You are 18 or older - You have an advanced or metastatic solid tumor with a confirmed RAS gene mutation (KRAS, HRAS, or NRAS) - You are in reasonably good functional health (ECOG 0 or 1) - Your cancer has progressed or you were unable to tolerate prior standard treatment **You may NOT be eligible if...** - You have untreated or active brain metastases - You have had serious heart problems, including recent heart attack or significant heart failure - You have active autoimmune disease requiring treatment - You are pregnant or breastfeeding - You have squamous cell lung cancer (for certain treatment groups) Talk to your doctor to see if this trial is right for you.